logo
Regulatory Challenges for NPs, PAs — How to Keep Up

Regulatory Challenges for NPs, PAs — How to Keep Up

Medscapea day ago

A roadside rest stop isn't the typical place to meet up with your patient. But it worked for Johnny L. Rollins, MSN, APRN, ANP-C, a nurse practitioner (NP) and associate director of the Advanced Practice Provider Programs — survivorship at the University of Texas MD Anderson Cancer Center, Houston — and his patient who lived in Louisiana.
As a licensed provider in Texas, he can't practice medicine in another state unless licensed there as well. Rollins said his patient needed a telemedicine visit.
'A telemedicine visit is technically a billable clinic visit,' Rollins told Medscape Medical News, 'and compliance with state and federal telemedicine law is required.'
As a result, he said, this patient and some others from Louisiana, have driven across the Louisiana-Texas state line, parked at a welcome area rest stop, and then started the video clinic visit to meet compliance requirements.
Rollins' story illustrated how keeping up with regulations is necessary — but also a challenge, not only for physicians but also for the 280,140 NPs and the 152,103 physician assistants/associates (PAs) practicing in the US.
Changes regulating both NP and PA practices, some said, have increased in recent years, sometimes spurred by COVID-related changes. Staying up to date is crucial, as not paying attention could jeopardize a healthcare worker's practice. Despite the challenge, many sources of information can help NPs and PAs stay up to date.
Who Regulates?
Beyond federal and state legislation regulating how NPs and PAs practice, healthcare organizations may have additional policies, so it's crucial to be aware of all of them, experts said.
For PAs, while there is some variation in state law, 'the majority of states have abandoned the concept that a medical board or other regulatory agency should make decisions about scope of practice details for individual PAs,' according to the American Academy of Physician Associates, Alexandria, Virginia. Rather, most states allow the scope of practice details to be decided at the practice level.
For NPs, the American Association of Nurse Practitioners, Austin, Texas, offered state-by-state practice information, with information on the regulatory structure (full practice, restricted, and reduced), regulatory agency, continuing education hours needed for licensure, signature authority, and other requirements.
Changes, Fast and Varied
Staying up to date on regulatory changes and requirements is more difficult these days, said Susan S. VanBeuge, DNP, APRN, FNP-BC, a professor in residence at the University of Nevada, Reno, and a practicing NP. She cited more changes in requirements on both the state and national level in recent years than in the past.
Deborah Busch, DNP, RN, CRNP, CPNP-PC, IBCLC, CNE, FAANP
'One of the biggest challenges for NPs is the variation in state law,' said Deborah Busch, DNP, RN, CRNP, CPNP-PC, IBCLC, CNE, FAANP, an NP and associate professor at Johns Hopkins School of Nursing, Baltimore. The regulatory environment has been 'more of a moving target the last 5 years or so,' she said. She cited COVID-19 as one reason, explaining it was accompanied by the expansion of some services, but now, as some are going away, close attention is needed to know what stays and what goes.
'The rapid pace of regulatory change in the current environment can be complex,' agreed Todd Pickard, DMSc, PA-C, a PA at the MD Anderson Cancer Center, who cares for patients and also serves as executive director of Advanced Practice at the Cancer Center.
As complex as these regulatory shifts can be, Jennifer Orozco-Kolb, DMSc, PA-C, chief medical officer at the American Acad emy of Physician Associates, pointed out that one of the core competencies for every PA is staying informed about evolving laws and regulations.
'The volume of regulatory changes impacts the entire healthcare team,' she said. So, a change in, for instance, a fee schedule will affect all providers who offer that care, she said.
Primary Issues
What regulatory issues most concern NPs and PAs?
'The primary issues concern reimbursement, patient eligibility, and care modalities, as well as assisting patients in navigating their coverage,' Pickard said.
Regulatory compliance in telehealth was important, as Rollins, the NP who has had rest area telehealth visits, knew. In most cases, he said, other communication with the patient can be handled by HER platform messaging; it's the telehealth visit with an out-of-state resident that's the logistical challenge.
Susan S. VanBeuge, DNP, APRN, FNP-BC
Continuing education requirements could also change, as VanBuege knew. In Nevada, for instance, the state nursing board requirements for continuing education in cultural competency changed recently. 'It went from 2 hours at regular intervals to now 4 hours of continuing education [in cultural competency],' VanBeuge said.
A delay in license renewal might occur if an NP applied for renewal without those required 4 hours included in the continuing education, she said.
That's why it's so important to keep an eye on the legislative proceedings in the state that an NP or PA practices in, she said. 'Our legislature meets every 2 years,' she said of Nevada. 'During that time, anything can happen within those 2 years.' Changes often do occur that affect healthcare providers, she said.
Changes in guidelines for the COVID vaccine, issued in late May, are another example of the need to stay current on policy changes, Orozco-Kolb said. Those changes are dramatic, going from recommending everyone 6 months or older get vaccinated to limiting access to those older than 65 years or younger people with a risk factor for severe COVID.
It's important to know the policy of a hospital network, Busch said. For instance, 'a state board of nursing may allow [NPs] to do a certain procedure, but a hospital network may have an internal policy restricting it.' The limitation isn't always about ability, she added. Rather, a hospital may already have a team in place that provides that procedure, she said.
Sources of Help
Policy courses are part of the education, said George Zangaro, PhD, RN, associate director of the DNP Executive Track at the Johns Hopkins School of Nursing. So, he said, simulations of regulatory cases are to prepare for the real world. 'We put a heavy emphasis on clinical, ethical, and legal responsibilities that NPs have in practice.'
How to keep current on regulations in the most efficient way?
'I turn to my practice leadership, financial teams, my colleagues, and, in many cases, professional associations such as the American Society of Clinical Oncology (ASCO),' Pickard said. He acknowledged how time-consuming it is, taking time away from other responsibilities, but also noted how critical it is to both his patients and his practice.
Likewise, Rollins said, he turns to colleagues and consults the legal and compliance teams at the MD Anderson Cancer Center.
George Zangaro, PhD, RN
'Once out of school, to keep up, continuing education is important,' Zangaro said, beyond the required hours. He encourages graduates to attend conferences regularly. 'Most conferences have a regulatory session included in them, depending on the current hot issues.' Membership in the NP and PA organizations has built-in tools to help, the organizers pointed out.
The American Association of Nurse Practitioners offers information on frequently asked questions about government policy, additional information on policy tracking, and a government affairs update newsletter that is for members only.
The American Academy of Physician Associates offers insight on requirements, certification, state licensing, and maintaining certification. (While the organization, the American Academy of Physician Associates, uses only 'associates,' not 'assistants,' Oregon is so far the only state to adopt the title change to associate, effective June 6, 2024.)
Turn to 'trusted sources,' Zangaro said, such as the National Council of State Boards of Nursing, the Centers for Medicare & Medicaid Services, and national associations such as the American Nurses Association.
While many sources of help are available for staying current with regulations, VanBeuge emphasized that the responsibility is on the shoulders of the healthcare practitioner.
'It's on you as the license holder to be responsible to know what is happening, and not the regulatory body's responsibility to tell you.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Most Chronic Hepatitis B Diagnoses in US Are Late
Most Chronic Hepatitis B Diagnoses in US Are Late

Medscape

timean hour ago

  • Medscape

Most Chronic Hepatitis B Diagnoses in US Are Late

More than 75% of chronic hepatitis B diagnoses in the United States occur late — within 2 years before or after the onset of a liver complication — highlighting the need for improved screening to prevent poor outcomes. METHODOLOGY: Late diagnosis of chronic hepatitis B represents a missed opportunity to intervene early and prevent liver-related complications. Researchers conducted a retrospective analysis of the Truven MarketScan database (2007 to 2021) to estimate the prevalence of late diagnosis of chronic hepatitis B in the US and associated liver complications. Eligible patients had chronic hepatitis B diagnosis and at least 12 months of insurance coverage prior to the first liver complication (cirrhosis, hepatocellular carcinoma [HCC], or liver transplant). A diagnosis was defined as late if it occurred within 2 years before or after the first liver complication, and non-late if was made more than 2 years before the complication. TAKEAWAY: Of 2608 patients included (mean age, 54.83 years; 29.7% women), 76.6% had a late diagnosis of chronic hepatitis B; among these, 44.5% were diagnosed at or within 6 months of their first liver complication, and 75.5% lacked a documented visit to a medical provider prior to their first liver complication. Among those diagnosed > 36 months after the first liver complication, 46% already had another liver disease. Despite treatment advances, the rate of late diagnosis remained stable between 2010 (78.8%) and 2019 (89.3%; P for trend = . 438). for trend 438). Among patients with a late diagnosis, 91.0% had cirrhosis, 81.5% had decompensated cirrhosis, 30.8% developed HCC, and 14.4% underwent liver transplant. Independent predictors of late diagnosis included male sex, alcohol use, and having Preferred Provider Organization (PPO) or Health Maintenance Organization/PPO hybrid insurance. IN PRACTICE: 'Our study suggests that the majority of [hepatitis B virus] diagnoses in the United States are likely incidental from the work-up of a liver complication. These patients can be seen as 'missed opportunities' for treatment and intervention to prevent disease progression and adverse hepatic outcomes,' the authors wrote. SOURCE: This study was led by Michael Le and Joanne K. Liu, Stanford University Medical Center, Stanford, California. It was published online in Alimentary Pharmacology & Therapeutics . LIMITATIONS: This study excluded uninsured individuals and those covered by government insurance (eg, Medicaid), potentially underrepresenting higher-risk populations. Reliance on claims data may have affected the accuracy of diagnosis rates. Data on race, ethnicity, and foreign-born status were unavailable, preventing analysis of these important factors. DISCLOSURES: The authors received no specific funding for this work. No conflicts of interest were disclosed by the authors.

Adverse Events Post-Colonoscopy Rise With Age but Are Rare
Adverse Events Post-Colonoscopy Rise With Age but Are Rare

Medscape

time2 hours ago

  • Medscape

Adverse Events Post-Colonoscopy Rise With Age but Are Rare

Although adverse event rates within 30 days after surveillance colonoscopy increase with age, peaking among patients aged 76-85 years, they remain infrequent, occurring in < 1% of procedures. METHODOLOGY: Guidelines recommend surveillance colonoscopy for patients with precancerous adenomas due to an increased colorectal cancer risk but lack recommendations for stopping surveillance after the age of 75 years despite older adults experiencing increased comorbidities. Researchers analyzed data from 84,172 surveillance colonoscopies performed from 2010 to 2019 within a large integrated US healthcare system. Participants (59.5% men; 66.4% White individuals), aged 45-85 years, had a prior adenoma and were followed up to 30 days post-procedure for adverse events. Outcomes included emergency department visits, hospitalizations, and deaths due to specific conditions (eg, colonic perforation and stroke), cardiovascular conditions, or any cause. Logistic regression was used to assess the association between age and adverse event risk, adjusting for various factors. TAKEAWAY: Adverse events occurred in < 1% of procedures, with gastrointestinal bleeding being the most common. Adverse event rates increased with age, with the highest rates observed in patients aged 76-85 years (69.6 events per 10,000 procedures), particularly for gastrointestinal bleeding (39.2 events per 10,000 procedures) and stroke (18.3 events per 10,000 procedures). Patients aged 76-85 years had significantly higher odds of adverse events than younger age groups in unadjusted analyses, but these odds were attenuated after adjusting for covariates. Significant risk factors for adverse events across all age groups included anticoagulant use, higher comorbidity scores, polypectomy, and advanced neoplasia detection during surveillance colonoscopy. IN PRACTICE: 'The findings suggest that the decision to perform colonoscopy surveillance after age 75 should be individualized based on patient preference, prior colonoscopy findings and procedure quality, comorbidities, and medication usage, rather than age alone,' the authors wrote. SOURCE: This study was led by Jeffrey K. Lee, MD, Kaiser Permanente Northern California in Oakland, California. It was published online in Clinical Gastroenterology and Hepatology . LIMITATIONS: Findings may not be generalizable, as all participants were insured and had access to comprehensive care. The observational design lacked a noncolonoscopy comparison group, making it difficult to attribute adverse events directly to the procedure. Limited numbers of certain adverse events resulted in wide CIs, and potential confounders like polyp size or number and sedation type were not adjusted for. DISCLOSURES: This study was conducted within the National Cancer Institute-funded Population-based Research to Optimize the Screening Process consortium and supported by a career development grant from the same agency. The authors reported no relevant conflicts of interest.

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Medscape

time3 hours ago

  • Medscape

Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology (ASCO) 2025 annual meeting. The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA (ctDNA). METHODOLOGY: The phase 3 CheckMate 816 trial has shown that compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint. The median follow-up duration was 68.4 months. TAKEAWAY: The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% (hazard ratio [HR], 0.72; P = .048). = .048). Among patients who received the combination therapy, the 5-year overall survival rate was 95.3% for those who achieved a pathological complete response vs 55.7% for those who did not. Overall, 24% of patients in the nivolumab group achieved a pathological complete response vs only 2.2% in the chemotherapy group. ctDNA clearance before surgery was a strong prognostic indicator, regardless of treatment. At 5 years, overall survival was 75.0% among patients with ctDNA clearance vs 52.6% in those without (HR for death, 0.38 in the nivolumab group and 0.39 in the chemotherapy-only group). The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths related to a trial treatment. IN PRACTICE: 'In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,' the authors wrote. 'These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient's life when paired with the curative potential of surgical resection.' SOURCE: This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland, was published online in The New England Journal of Medicine and presented at ASCO. LIMITATIONS: Although the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings. DISCLOSURES: This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store